Farber, a Harvard pathologist and cancer researcher, was one of Lasker's most stellar "citizen witnesses" before
Congress and an ardent supporter of NCI's chemotherapy program, which he hailed as "the greatest mobilization of resources--man,
mineral, animal, and money--ever undertaken to conquer a single disease." He had discovered in the early 1950s that treatment
with anti-folic acid compounds resulted in permanent remission of acute leukemia in children; the first time physicians had
been able to produce such a remission. After the recent discovery of penicillin and streptomycin had given physicians unprecedented
control over infectious diseases, Farber's discovery seemed to confirm the possibility that scientists would discover
a "magic bullet" against cancer.
Number of Image Pages:
3 (248,447 Bytes)
1955-08-19 (August 19, 1955)
Harvard Medical School. Children's Hospital
Original Repository: Columbia University. Rare Book and Manuscript Library. Mary Lasker Papers
Courtesy of the Albert and Mary Lasker Foundation.
The National Library of Medicine's Profiles in Science
program has made every effort to secure proper permissions
for posting items on the web site. In this instance, however,
it has either not been possible to identify or contact the
current copyright owner.
If you have information regarding the copyright owner,
please contact us at
Please forgive a typed letter. My handwriting is too far gone to be deciphered. I appreciated very much your good letter and
hope that the European tour has been everything you desired. There is unfortunately no happy news to report about the growth
hormone in acute leukemia. We have not had enough of it to give it a fair trial. A few patients to whom it was given showed
no response which we could ascribe to the growth hormone, except continued survival beyond the point we would have thought
possible. We must use adequate quantities to permit ourselves a fair evaluation.
I am awaiting news from C.H. who promised before he went away to have more material by the end of the month. I shall keep
We have started our new program with Gregory Pincus. I can't tell you how pleased I am that you brought the two of us
together. He was here the other day for a conference. I am looking forward to good results from this collaboration.
John Fogarty phoned me from Providence to let me know that he had accepted two invitations to speak in behalf of the Jimmy
Fund. (A trustee who lived in Providence and who is a supporter of John's apparently invited him to perform this gracious
act). He is starting off for a 5-6 weeks tour of Europe. When he returns he told me he will accept my invitation to have diner
with me in Boston so that we may discuss the problems of mutual interest, at leisure.
I have been in constant touch with Ken Endicott and the National Chemotherapy program. I do believe that the organizational
pattern is developing at a much more rapid rate than I could have hoped. It nevertheless seems frightfully slow. It sometimes
becomes monotonous to see more and more men brought into the program go through the joys of discovering America. The enthusiasm,
however, of these new friends of chemotherapy is refreshing and seems to be on a genuine foundation.
The two million dollars has dwindled to a disturbingly small amount after the June commitments and the extra overhead percentage
were taken away. Approximately $900,000 had been set aside for contracts.
I am going to Washington on the 23rd for conferences with Endicott, Van Slyke, and other people in the chemotherapy program
to see if I can help unravel some of the tangles and help make new plans. The Screening Panel will meet the 29th and 30th
at New London, New Hampshire at the Gordon Cancer Conference. Great progress has been made by Harry Eagle in Bethesda and
George Foley here in the growth of human tumors in Eagle's new medium. It is not yet ready for mass screening but may
well prove to be the method for which we have been searching.
The other panels will be meeting in mid-September. We have set a date for the cancer chemotherapy national committee. I have
called the meeting for New York on October 21st, which I have been told is convenient for you. All of the panels will have
had a chance to meet sufficiently to have recommendations to present to the National Committee. Earlier than that, however,
I think it will be quite important to have a meeting of the Sub-Committee of the National Advisory Cancer Council. We shall
try to arrange for a time sometime during the week of 19th of September.
Our staff at what is now called by them the Cancer Chemotherapy National Service Center I know will appreciate knowing the
wishes of the Sub-Committee. We will have to have someone to take the place of Dr. DeCoursey who has left the Council and
has gone, as you know to San Antonio. Dr. Ravdin has been mentioned, particularly since he is the Chairman of the Clinical
I have just learned that Dr. Robert Moore, formerly Dean and Professor of Pathology, Washington University, St. Louis, and
presently Vice-Chancellor in charge of the Health Schools at the University of Pittsburgh, has been appointed to the Cancer
Council. I have not heard of any other appointments. Dr. Moore spent several hours with me the other evening in discussion
of the Council and the Cancer Chemotherapy Program in particular. Dr. Moore is noted particularly for his administrative decorum
and committee participation. He is a man of integrity and courage, has not done any cancer research but does have a good understanding
of the pathologic basis of cancer.
Waksman's Actinomysin D appears to have its greatest effect upon the rhabdomyosarcoma, which is one of the most malignant
tumors we have. We have not yet been able to achieve in man what we had hoped from the mouse work but we are still working.
We reviewed just today the extraordinary effectiveness of Actinomycin D followed by nitromen (A Japanese milder relative of
nitrogen mustard) on the extensive destructive lesions of the skeleton of a one year old child caused by an angiosarcoma.
The massive destructive lesions have melted away during the last three months of treatment and the baby has actually learned
to walk during that period. We are trying the combination as rapidly as we can in other equally disturbing situations.
We feel somewhat more happy too because of developments in another part of the program--a new class of pyrimidines synthesized
five years ago and since then by several other industrial laboratories have been on the shelf as chemicals unstudied during
this time. We re-discovered them here a year ago, and since none of the industrial laboratories had published we were unaware
of their works. We found them to have strong anti-folic and anti-purine activity. One of my younger colleagues, Dr. Edward
Modest has just returned from the International Biochemical Congress in Brussels. There he learned that some of Haddow's
men had studied these compounds and found them to be anti-folic in activity. They had not looked for anti-purine activity.
This group of pyrimidines now has assumed biological importance in experimental cancer chemotherapy. We have been pushing
ahead as fast as possible during the last several months in our biological studies but have not yet reached man. In action
they seem to combine the virtues of aminopterin and 6-mercaptopurine. I am always pleased when discoveries are made in two
Institutions far apart at about the same time. This saves so much time in confirmation of work.
The polio situation in Boston has remained in the state of a moderate epidemic. Our hospital has been filled and we have had
8 deaths so far. This combined with the hottest summer in history has made going a little tough but our splendid staff has
carried on in a surprisingly effective manner under bad conditions.
I had not intended to make this a scientific treatise. The hour is very late, Mrs. McGachie is long suffering, and the psychiatrists
call this catharsis. All of us are looking forward to your return. With all good wishes for a happy remainder of your stay,